Danielle N. Margalit

Danielle N. Margalit

Auto-generated profile, based on publicly available information

Danielle N. Margalit

Dana-Farber Cancer Institute 4 Department of Radiation Oncology Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
BMBrandon A. Mahal
Brandon A. Mahal
PCPaul J. Catalano
Paul J. Catalano
RHRobert I. Haddad
Robert I. Haddad
GHGlenn J. Hanna
Glenn J. Hanna
JKJason I. Kass
Jason I. Kass
DMDanielle N. Margalit
Danielle N. Margalit
Background: Human papillomavirus (HPV)-positive oropharyngeal head and neck squamous cell carcinoma (OPSCC) is increasing in the United States. Current epidemiologic assessments of the national burden of HPV-positive OPSCC are needed. Methods: The Surveillance Epidemiology and End Results HPV Status Database included 12,017 patients with head and neck squamous cell carcinoma of pharyngeal subsites, including OPSCC and non-OPSCC head and neck cancer subsites (hypopharynx, nasopharynx, and “other pharynx”), diagnosed from 2013 to 2014. Age-adjusted incidence rates per 100,000 persons by HPV status were calculated. An exploratory Fine-Gray competing-risks regression determined the associations between HPV status and cancer-specific mortality. Results: From 2013 to 2014, the U.S. incidence of HPV-positive OPSCC was 4.62 [95% confidence interval (CI), 4.51–4.73] versus 1.82 (95% CI, 1.75–1.89) per 100,000 persons for HPV-negative OPSCC. The incidence of HPV-positive versus negative non-OPSCC of the head and neck was 0.62 (95% CI, 0.58–0.66) versus 1.38 (95% CI, 1.32–1.44). White race (5.47) and male sex (8.00) had the highest incidences of HPV-positive OPSCC, with a unimodal age incidence distribution peaking at ages 60 to 64 years (27.23). HPV positivity was associated with lower cancer-specific mortality than HPV-negative disease for OPSCC [adjusted HR (aHR), 0.40; P < 0.001], but not non-OPSCC (aHR, 1.08; P = 0.81), Pinteraction = 0.002. Conclusions: The U.S. incidence of HPV-positive OPSCC was 4.62 per 100,000 persons. Most cases were found in white male patients younger than 65 years, where it represents the sixth most common incident nonskin cancer. The favorable prognosis associated with HPV appears to be limited to the oropharynx. Impact: This large population-based epidemiologic assessment of the U.S. population defines the incidence and demographic burden of HPV-positive OPSCC.

2 June 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GHGlenn J. Hanna
Glenn J. Hanna
MDMichael J. Dennis
Michael J. Dennis
NSNicole Scarfo
Nicole Scarfo
MMMichelle S. Mullin
Michelle S. Mullin
RSRosh K.V. Sethi
Rosh K.V. Sethi
EREleni M. Rettig
Eleni M. Rettig
Purpose: Many patients with locoregionally advanced human papillomavirus–negative head and neck squamous cell carcinoma (HNSCC) relapse. ctDNA has the potential to identify minimal residual disease, but its clinical utility for virus-negative HNSCC is not well understood. Experimental Design: We retrospectively evaluated a personalized, commercial ctDNA assay (Signatera, Natera) during clinical care of patients treated for predominantly newly diagnosed human papillomavirus–negative HNSCC. Signatera utilizes 16-plex PCR from matched tumor and blood. Objectives were to understand ctDNA detectability and correlate changes posttreatment with disease outcomes. Results: Testing was successful in 100/116 (86%) patients (median age: 65 years, 68% male, 65% smokers); testing failed in 16 (14%) because of insufficient tissue. Oral cavity (55, 47%) tumors were most common; most had stage III to IV disease (82, 71%), whereas 17 (15%) had distant metastases. Pretreatment, 75/100 patients with successful testing (75%) had detectable ctDNA (range: 0.03–4049.69 mean tumor molecules/mL). No clinical features predicted ctDNA detectability or levels (multivariate analysis). At a median follow-up of 5.1 months (range: 0.2–15.1), 55 (55%) had >1 test result (range: 1–7; 194 samples). Of 55 patients, 17 (31%) remained ctDNA positive after starting treatment. Progression-free survival was significantly worse for patients who were ctDNA positive versus ctDNA negative posttreatment (HR, 7.33; 95% confidence interval, 3.12–17.2; P < 0.001); 1-year overall survival was 89.1% versus 100%, respectively (HR, 7.46; 95% confidence interval, 0.46–119.5; P = 0.155). Conclusions: Tumor-informed ctDNA testing is feasible in nonviral HNSCC. ctDNA positivity is an indicator of disease progression and associated with inferior survival. Further research is warranted to understand whether ctDNA may be leveraged to guide therapy in HNSCC.

18 June 2024 in Practical Radiation Oncology
Verified
Journal Article
Closed access
DMDanielle N. Margalit
Danielle N. Margalit
CAChristopher J. Anker
Christopher J. Anker
MAMichalis Aristophanous
Michalis Aristophanous
MAMusaddiq Awan
Musaddiq Awan
GBGopal K. Bajaj
Gopal K. Bajaj
DSDavid J. Sher
David J. Sher

23 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
EREleni M. Rettig
Eleni M. Rettig
JSJonathan D. Schoenfeld
Jonathan D. Schoenfeld
JMJulianna Miller
Julianna Miller
BSBethany Sargent
Bethany Sargent
ECEvan Carey
Evan Carey
GHGlenn J. Hanna
Glenn J. Hanna
Purpose: Observational studies suggest circulating tumor human papillomavirus (HPV) DNA may facilitate early detection of recurrent HPV-positive oropharynx cancer. We prospectively investigated whether biomarker-guided surveillance detects recurrence earlier than the standard-of-care methods. Patients and Methods: We enrolled patients evaluated for HPV-positive oropharynx cancer at a single center from November, 2020, to April, 2023, undergoing curative-intent treatment in a single-arm cohort study. Pretreatment plasma and/or tumor tissue were tested for tumor tissue–modified viral (TTMV) HPV DNA from HPV subtypes 16/18/31/33/35 using a droplet digital PCR–based commercial assay. Posttreatment plasma TTMV was assessed periodically. Detectable/indeterminate tests prompted imaging. The primary outcome was the proportion of recurrences first detected by TTMV. Results: Median follow-up was 23 months, with median six posttreatment TTMV tests for 155 subjects. Fifteen subjects (9%) experienced recurrence. Among these, six [40%, 95% confidence interval (CI) = 16%–68%] were “early true-positives,” for whom TTMV detection predated and prompted the imaging and clinical workup that diagnosed recurrence (median lead time = 132 days; range = 47–280). Another five subjects (33%) were “confirmatory true-positives,” for whom detectable TTMV confirmed suspicious standard-of-care imaging findings. Finally, four subjects (27%) with recurrence had undetectable TTMV at diagnosis (“false-negatives”). False-negatives had low or undetectable pretreatment TTMV, and 2/4 had non-HPV16 genotypes. Finally, three subjects had prolonged detectable TTMV without disease (“false-positives”); all had immunologic comorbidities. Overall, the sensitivity of TTMV for recurrence was 73% (95% CI = 45%–92%). Among 117 subjects with HPV16 and detectable pretreatment TTMV, sensitivity was higher (91%, 95% CI = 59%–100%). Conclusions: TTMV-guided surveillance facilitates early detection of many HPV-positive oropharynx cancer recurrences, with the highest sensitivity for HPV16 and detectable pretreatment TTMV. Clinical implementation should be carefully informed by the limitations described in this study. See related commentary by Califano, p. 1561

1 June 2020 in Oral Oncology
Verified
Journal Article
Closed access
AKAlec Kacew
Alec Kacew
EHEthan J. Harris
Ethan J. Harris
JLJochen H. Lorch
Jochen H. Lorch
JSJonathan D. Schoenfeld
Jonathan D. Schoenfeld
DMDanielle N. Margalit
Danielle N. Margalit
GHGlenn J. Hanna
Glenn J. Hanna

13 January 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
ZFZoe H. Fullerton
Zoe H. Fullerton
SBSantino S. Butler Ba
Santino S. Butler Ba
BMBrandon A. Mahal
Brandon A. Mahal
VMVinayak Muralidhar
Vinayak Muralidhar
JSJonathan D. Schoenfeld
Jonathan D. Schoenfeld
DMDanielle N. Margalit
Danielle N. Margalit